PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (October 2026)
37 slides from PetVivo's investor presentation, October 2026
Slide 1: Investor Presentation
Investor Presentation October 2026 PETV (OTCQB)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those
Slide 3: PetVivo - Subsidiaries Org Chart
PetVivo - Subsidiaries Org Chart PetVivo Holdings, Inc. (PETV) PetVivo AI, Inc. Somatrix Technologies, Inc. Gel-Del Technologies, Inc. PetVivo Animal Health. Inc. Human Product R&D and Sales Manufacturer of All Human and Veterinary AI Product Sales Sales Entity for all Vet Products Entity Vet Produc
Slide 4: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary Growth Drivers care and product sales market with ~ 6% Innovation historical CAGR (2020-2024)* Strategic partnerships with experts in functional materials for innovation and product expansion of regenerative product portfol
Slide 5: Osteoarthritis (OA) Opportunity
Osteoarthritis (OA) Opportunity $39.8B Veterinary Care and Product Sales Market Osteoarthritis: Current solutions treat a common affliction symptoms, but do not of the joints manage the cause • Affects approximately 34 million • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) adult dogs and 1 million
Slide 6: Viscosupplementation
Viscosupplementation A strong hydrated biomaterial that facilitates enhanced lubrication and joint-cushioning properties. Micro-scaffolds Over time, micro-scaffolds adhere to and integrate with the existing synovial membrane. Collagen-Elastin Microparticles Porous, spongy particles absorb and releas
Slide 7: An Optimal OA Solution: Spryng with OsteoCushion Technology
An Optimal OA Solution: Spryng® with OsteoCushion® Technology ● Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function ○ Similar components/function found in natural cartilage (i.e. collagen, elastin and he
Slide 8: Spryng with OsteoCushion Technology
Spryng® with OsteoCushion® Technology ● Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms ● Purified natural components self-assemble to form an insoluble, hydrated matrix ● Protein source bovine tissues (i.e. medical grade collagen and elastin)
Slide 9: Spryng Mechanism of Action
Spryng® Mechanism of Action ● An animal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain, and further loss of cartilage ● Spryng reinforces synovial membrane function, without
Slide 10: Spryng Canine Success: Koda
Scan to read Koda’s story Spryng® Canine Success: Koda Condition Treatment Results¹ ● 4-year-old FS Labrador ● Koda’s rehabilitation team ● Within 24 hours, Koda’s Retriever recommended Spryng as an desire to walk returned, ● Koda developed a persistent option to help address her along with noticeab
Slide 11: Spryng Equine Success: Red
Scan to read Red’s story Spryng® Equine Success: Red History Treatment Results¹ ● 26-year-old Quarter Horse ● Red remained painful and ● Day 1: That evening, gelding his mobility was Red was observed significantly affected, trotting to greet his ● Red was diagnosed with prompting the need for a owne
Slide 12: Spryng Canine Success: Pratchett
Scan to read Pratchett’s story Spryng® Canine Success: Pratchett Condition Treatment Results¹ ● 7-year-old MN Smoke ● Pratchett underwent ● Just three weeks after Tabby Shorthair surgical repair of his right surgery and treatment, ● Pratchett developed right cranial cruciate ligament Pratchett showe
Slide 13: Spryng Competitive Distinctions
Spryng® Competitive Distinctions ● Outcomes address affliction/not just symptoms ● Current treatments rely on biologic activity to treat symptoms; Spryng provides structural components to address affliction ● Price/Cost advantage ● Derived from all natural materials ● Ease of application ● Vet clini
Slide 14: Spryng Product Category Comparison
Spryng® Product Category Comparison *NSAIDs: Rimadyl *Orthobiologics Arthramid Features Spryng® Librela Solensia Adequan HA/Legend Synovetin Banamine PRP, APS Noltrex Injections per Year 1 12 16-18 N/A 3-4 2-3 1 Benefits Last up to 12 Months or More x x x Bioscaffold From Naturally-Derived x Compone
Slide 15: Spryng Tolerance Studies
Spryng® Tolerance Studies Canine Tolerance Feline Tolerance Purpose: Assess tolerance of Spryng® Purpose: Assess tolerance of Spryng® administration in dogs. administration in cats. Design: 20 healthy dogs received intra-articular Design: 10 healthy female cats received intra- injection with saline
Slide 16: Spryng Clinical Studies
Spryng® Clinical Studies Six Clinical Trials Conducted To Date — All With Positive, Confirming Results Canine Hip OA Canine Stifle OA/CCL Disease Purpose: Study the effects of Collagen-Elastin Purpose: Evaluate benefit and tolerability of an intra- Hydrogel Microparticles (Spryng) on pain & function
Slide 17: Spryng Peer-Reviewed Studies
Spryng® Peer-Reviewed Studies Equine Joint Inflammation Canine Elbow OA Purpose: Evaluate whether Collagen-Elastin Hydrogel Purpose: Evaluate the tolerance and efficacy of an intra- Microparticles (CEHM) affect inflammatory responses in articular injection of collagen-elastin hydrogel equine cartila
Slide 18: New Spryng Clinical Trials
New Spryng® Clinical Trials Additional Studies 2025 - 2026 Underway or Recently Completed, Awaiting Publication Canine Study at Colorado Canine Study Canine Study State University Principal investigators: Principal investigators: Principal investigators: Felix ● Jamie Gaynor DVM, MS, ● Sherman Canap
Slide 19: Functional Biomaterials Platform
Functional Biomaterials Platform CEHM + Piezoelectric Fibers ● Builds upon PetVivo's proprietary collagen-elastin hydrogel microparticle (CEHM) technology ● Incorporates embedded piezoelectric fibers to create mechanically responsive biomaterials ● CEHM microscaffolds are engineered to adhere to and
Slide 20: What are Functional Biomaterials?
What are Functional Biomaterials? Potential Advantages of PetVivo’s Functional Biomaterials Platform Advanced materials engineered to interact with the biological environment and provide specific functional • Biointegrative: CEHM microscaffolds are designed to properties. adhere to and integrate wit
Slide 21: Potential Applications for Functional Biomaterials in Veterinary Medicine
Potential Applications for Functional Biomaterials in Veterinary Medicine Respiratory and Airway Wound Healing Post Surgical Healing Ophthalmic Uses Dental and Oral ● Corneal Ulceration ● Keratoconjunctivitis Sicca Surgical Procedures ● Descemetocele Musculoskeletal Disease/Injury ● Osteoarthritis ●
Slide 22: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities ● Spryng® product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 ● Current production batches of 2,000 syringes, with the ability to scale to 4,000+ syringes per month ● Current production facility annual capacity is approximatel
Slide 23: Comprehensive IP Portfolio
Comprehensive IP Portfolio ● 10 US and Foreign Issued Patents and 2 additional pending ● Broad Claim Language - “Comprising” Transitions ● 6 Detailed Proprietary Trade Secrets ● Our Patents & Trade Secrets Protect: ○ Protein & Carbohydrate Based Thermoplastics ○ Biomaterials of Many Compositions ○ M
Slide 24: Market Overview
Market Overview Sources: American Pet Products Assoc.; North American Pet Health Insurance Association, American Horse Council, LendEDU Companion Animal/Veterinarian * Agricultural and professional equine markets not included ● US Pet Spend increased from $152B in 2024 to $157B in 2025 ● Veterinary
Slide 25: Animal Product Pipeline
Animal Product Pipeline No FDA Review or Clearance Required for Commercialization of Veterinary Medical Devices FDA clearance not required Product Commercial Particle Based Devices Species Safety Pilot Efficacy No. Launch VD-01 Osteoarthritis Canine (Spryng®) Q3 2021 VD-02 Osteoarthritis Equine (Spr
Slide 26: Human Product Pipeline
Human Product Pipeline FDA Review or Clearance Required for Commercialization of Human Medical Devices FDA clearance required Product Commercial Particle Based Devices Species Safety Pilot Efficacy No. Launch HD-01 Osteoarthritis Human (Spryng®) TBD HD-02 Osteoarthritis Human (Revivion ) TBD Human H
Slide 27: Distribution Partners
Distribution Partners MWI Animal Health Covetrus MWI – PetVivo Distribution Services Covetrus – PetVivo Distribution Services MWI Overview: Covetrus Overview: ● One of largest distributors of veterinary ● One of largest distributors of veterinary products in the world products in the world ● More th
Slide 28: Distribution Partners Cont.
Distribution Partners Cont. Patterson Veterinary Midwest Veterinary Supply Patterson Veterinary – PetVivo Distribution Midwest Veterinary Supply – PetVivo Patterson Veterinary Overview: Midwest Veterinary Supply Overview: ● One of the largest distributors serving ● 65-year veterinary distribution le
Slide 29: Wholesale Partners
Wholesale Partners Vedco Clipper Vedco – Wholesaler Engagement: Clipper – Wholesaler Engagement: ● Wholesaler relationship to purchase ● Non-exclusive distribution agreement product from PetVivo and sell it to with one year term that automatically national distributors for subsequent sale renews ann
Slide 30: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Exclusive White Label License What is Agentic Pet AI? Relationship: The world's first autonomous pet care AI ecosystem that leverages cutting-edge • Exclusive white label license agreement multi-agent technology to revolutionize how between
Slide 31: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Current Development Status Anticipated Launch Timeline and Third-Party Validation • January 2027 – Expanded B2B Beta & Readiness: : • Core multi-agent architecture completed and Expanded beta with select U.S. veterinary clinics and operatin
Slide 32: PetVivo Strategic Partners
PetVivo Strategic Partners PiezoBioMembrane, Inc. (“PBM”) and Veterinary Growth Partners (“VGP”) PBM (Functional Biomaterials) Veterinary Growth Partners (Veterinarian Association) Relationship – Master Services Agreement (Joint R&D): Relationship – Vendor Partner Agreement ● Collaboration on the re
Slide 33: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience John Lai Garry Lowenthal John F. Dolan Bryan Monninger Josh Wilhelm CEO, President & Director CFO General Counsel VP of Sales & Distributor VP of Operations & R&D Relations Andrea Cranston Kirsty Husby, DVM, MS,
Slide 34: Strong Independent Board of Directors and Advisors
Strong Independent Board of Directors and Advisors Advisors ▪ Dr. Tracy Turner, DVM, MS, Robert Costantino Dr. Jamie Pickett Robert Rudelius Michael Handley Dipl. ACVS, Dipl. ACSMR, Director Director Director Director Amer. Academy Thermology, AAEP Board Noble Ventures ▪ Dr. Sherman Cannap, DVM, MS,
Slide 35: Growth Drivers
Growth Drivers Functional Biomaterials Portfolio Expansion & Innovation ● Revivion — Next-generation joint product Sales Growth & Expansion combining CEHM technology with embedded ● US Direct Veterinary Sales Force piezoelectric fibers ● 100% US veterinary market coverage via ● Expanding CEHM + piez
Slide 36: Company Highlights
Company Highlights Market Opportunity +$39.8B US companion animal veterinary Growth Drivers care and product sales market with ~ 6% Innovation historical CAGR (2020-2024)* Strategic partnerships with experts in functional materials for innovation and product expansion of regenerative product portfol
Slide 37: John Lai
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 Spryng® with OsteoCushion® Technology is exclusively sold and distributed by PetVivo Animal Health. Veterinary Use Only - Federal law restricts this device to use by or on the order of a licensed veterinarian. 844-Pet-Vivo (844-738-848
PetVivo Holdings — Investor Presentation (October 2026) on 6ix